Abstract
A total of 34 leukemia and lymphoma samples (17 clinical samples and 17 cell lines) were analyzed for mutations of the Smad2 gene by reverse transcriptase-polymerase chain reaction single strand conformation polymorphism (RT-PCR-SSCP) analysis. Nine of the 34 samples had 18q chromosomal abnormalities. No shifted bands were detected in any of the hematological malignancies. Our results suggest that resistance to cell growth inhibitory effects of TGF-βin hematological malignancies is not due to alterations of the Smad2 gene.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ikezoe, T., Takeuchi, S., Kamioka, M. et al. Analysis of the Smad2 gene in hematological malignancies. Leukemia 12, 94–95 (1998). https://doi.org/10.1038/sj.leu.2400888
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2400888
Keywords
This article is cited by
-
TGFβ-induced SMAD2 phosphorylation predicts inhibition of thymidine incorporation in CD34+ cells from healthy donors, but not from patients with AML after MDS
Leukemia (2001)
-
Transforming growth factor-β and breast cancer: Transforming growth factor-β/SMAD signaling defects and cancer
Breast Cancer Research (2000)
